A highly annotated database of genes associated with platinum resistance in cancer.

A highly annotated database of genes associated with platinum resistance in cancer.
复制标题

DOI:
10.1038/s41388-021-02055-2
复制
发表时间:
2021-11
期刊:
影响因子:
8
通讯作者:
Paulovich AG
Paulovich AG
中科院分区:
医学1区
文献类型:
--
作者:
Huang D;Savage SR;Calinawan AP;Lin C;Zhang B;Wang P;Starr TK;Birrer MJ;Paulovich AG

文献摘要

参考文献

被引文献

相似文献

基于铂的化疗,包括顺铂、卡铂和奥沙利铂,被处方给所有癌症患者的10-20%。不幸的是,铂耐药性在相当数量的患者中发展,并且是临床结果的决定因素。已经进行了广泛的研究来理解和克服铂抗性,并且抗性的机制可以分为几个广泛的生物学过程,包括(1)药物进入、离开、积累、隔离和解毒的调节,(2)铂诱导的DNA损伤的增强的修复和耐受,(3)细胞存活途径的改变,(4)多效性过程和途径的改变,(5)肿瘤微环境的改变。作为癌症研究界的资源,我们提供了一个全面的概述,并附有一个手动管理的数据库,其中包含过去30年文献中与铂耐药性相关的>900个基因/蛋白质。该数据库注释了可能的途径,通过这些途径,策划的基因与铂类耐药相关,证据类型和文献来源的超链接。可在http://ptrc-ddr.cptac-data-view.org网站上查阅可供下载的数据库。
Platinum-based chemotherapy, including cisplatin, carboplatin, and oxaliplatin, is prescribed to 10-20% of all cancer patients. Unfortunately, platinum resistance develops in a significant number of patients and is a determinant of clinical outcome. Extensive research has been conducted to understand and overcome platinum resistance, and mechanisms of resistance can be categorized into several broad biological processes, including (1) regulation of drug entry, exit, accumulation, sequestration, and detoxification, (2) enhanced repair and tolerance of platinum-induced DNA damage, (3) alterations in cell survival pathways, (4) alterations in pleiotropic processes and pathways, and (5) changes in the tumor microenvironment. As a resource to the cancer research community, we provide a comprehensive overview accompanied by a manually curated database of the >900 genes/proteins that have been associated with platinum resistance over the last 30 years of literature. The database is annotated with possible pathways through which the curated genes are related to platinum resistance, types of evidence, and hyperlinks to literature sources. The searchable, downloadable database is available online at http://ptrc-ddr.cptac-data-view.org.
DOI: 10.1158/1078-0432.ccr-15-1468
发表时间: 2016-05-15
期刊: Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子: --
作者:
Bell EH;Chakraborty AR;Mo X;Liu Z;Shilo K;Kirste S;Stegmaier P;McNulty M;Karachaliou N;Rosell R;Bepler G;Carbone DP;Chakravarti A
通讯作者: Chakravarti A
DOI: 10.18632/oncotarget.13817
发表时间: 2017-01-03
期刊: Oncotarget
影响因子: --
作者:
Dai Y;Jin S;Li X;Wang D
通讯作者: Wang D
DOI: 10.1038/onc.2010.245
发表时间: 2010-09-02
期刊: ONCOGENE
影响因子: 8
作者:
Cooke, S. L.;Ng, C. K. Y.;Melnyk, N.;Garcia, M. J.;Hardcastle, T.;Temple, J.;Langdon, S.;Huntsman, D.;Brenton, J. D.
通讯作者: Brenton, J. D.
DOI: 10.1038/nature18325
发表时间: 2016-07-21
期刊: Nature
影响因子: 64.8
作者:
Ray Chaudhuri A;Callen E;Ding X;Gogola E;Duarte AA;Lee JE;Wong N;Lafarga V;Calvo JA;Panzarino NJ;John S;Day A;Crespo AV;Shen B;Starnes LM;de Ruiter JR;Daniel JA;Konstantinopoulos PA;Cortez D;Cantor SB;Fernandez-Capetillo O;Ge K;Jonkers J;Rottenberg S;Sharan SK;Nussenzweig A
通讯作者: Nussenzweig A
DOI: 10.1038/s41598-017-09206-0
发表时间: 2017-08-18
期刊: Scientific reports
影响因子: 4.6
作者:
Dar S;Chhina J;Mert I;Chitale D;Buekers T;Kaur H;Giri S;Munkarah A;Rattan R
通讯作者: Rattan R